AROMASIN 25 Milligram Coated Tablets
Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
Данни за продукта
(SPC)
25-04-2024
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
EXEMESTANE
Предлага се от:
Haemato Pharm AG
АТС код:
L02BG06
INN (Международно Name):
EXEMESTANE
дозиране:
25 Milligram
Лекарствена форма:
Coated Tablets
Вид предписание :
Product subject to prescription which may not be renewed (A)
Терапевтична област:
Aromatase inhibitors
Статус Оторизация:
Authorised
Дата Оторизация:
2012-11-30
Данни за продукта
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Aromasin 25 mg coated tablets.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance: exemestane
Each coated tablet contains 25 mg exemestane.
Each tablet contains 30.2mg of sucrose and 0.003mg of methyl parahydroxybenzoate (E218).
For a full list of Excipients, see section 6.1
3 PHARMACEUTICAL FORM
Coated tablet
_Product imported from Italy:_
Round, biconvex, off-white coated tablet marked 7663 on one side.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive
early breast cancer, following 2 – 3 years of initial adjuvant tamoxifen therapy.
Aromasin is indicated for the treatment of advanced breast cancer in women with natural or induced postmenopausal
status whose disease has progressed following anti-oestrogen therapy. Efficacy has not been demonstrated in patients
with oestrogen receptor negative status.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adult and elderly patients
The recommended dose of Aromasin is one 25 mg tablet to be taken once daily, preferably after a meal.
In patients with early breast cancer, treatment with Aromasin should continue until completion of five years of
combined sequential adjuvant hormonal therapy (tamoxifen followed by Aromasin), or earlier if tumour relapse occurs.
In patients with advanced breast cancer, treatment with Aromasin should continue until tumour progression is evident.
No dose adjustments are required for patients with hepatic or renal insufficiency _(see section 5.2, Pharmacokinetic_
_Properties)._
Children
Not recommended for use in children.
4.3 CONTRAINDICATIONS
Aromasin tablets are contraindicated in patients with a known hypersensitivity to the active su
Прочетете целия документ
